The Blue Pill and Pharma: A Dangerous Bet?

The story of Sildenafil offers a complicated case study for analysts eyeing pharma. While first sales were remarkable, current patent expiry and the arrival of cheaper versions have severely affected revenues. In addition, increasing regulatory scrutiny and pressure to decrease prescription price

read more